Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Cisplatinum and Everolimus in Patients With Metastatic or Unresectable Neuroendocrine Carcinomas (NEC) of Extrapulmonary Origin

NCT02695459 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.

NCT NCT02695459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02695459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Cisplatinum and Everolimus in Patients With Metastatic or Unresectable Neuroendocrine Carcinomas (NEC) of Extrapulmonary Origin
Lead sponsor
The Netherlands Cancer Institute
Phase
Phase 2
Overall status
Unknown status
Start date
March 30, 2016
Completion date
August 31, 2021
Enrollment
39 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine carcinomas